small molecule

TRYVIO

APROCITENTAN

Loss of exclusivityJuly 2038latest FDA-listed patent expiry

CompanyIdorsia →See this company's full patent-cliff portfolio

Drug detail

Brand name	TRYVIO
Active ingredient	APROCITENTAN
Strength	12.5MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11680058	July 2038	use U-3878
11787782	March 2038	use U-3877
12297189	February 2038	product
10919881	February 2038	substance, product
11174247	November 2037	use U-3879
8324232	September 2029	substance, product

Regulatory exclusivity

Code	Expires
NCE	March 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Idorsia